Lorus completes rights offering

Lorus Therapeutics (TSX: LOR) has completed its rights offering, raising $4.6 million before expenses, through the issue of 4.2 million units at a price of $1.11 a unit. Each unit consists of one common share and one warrant, which can be exercised to purchase an additional common share at a price of $1.33 until May [...]

Lorus pipeline in prime time

Lorus Therapeutics (TSX:LOR; OTCBB:LRUS.F) is putting the pedal to the metal and gearing up for a pivotal clinical trial by early 2011 and a Phase 1 clinical study for a first-in-class anti-cancer drug this year. “Our product potential has never been greater and we have a low cash burn rate,” CEO Dr. Aiping Young says [...]

Lorus files IND with FDA for LOR-253

Lorus Therapeutics (TSX: LOR; OTCBB: LRUSF) has filed an investigational new drug application with the FDA to conduct a Phase 1 trial with its anticancer drug candidate LOR-253. The IND is for a “first-in-man” dose escalation trial in advanced or metastatic solid tumours and will assess the safety profile, tolerability, and antitumor activity of LOR-253 [...]

Lorus gets first patent in China

Lorus Therapeutics (TSX:LOR) received allowance of its first patent in China for novel drug candidates from its small molecule program. The Chinese patent covers composition of matter for Lorus’ lead anticancer small molecule LOR-253, as well as composition and uses of its lead antimicrobial compound LOR-220.  Lorus has similar patents pending worldwide for the two [...]

Lorus announces 1-for-30 share consolidation

The board of Lorus Therapeutics (TSX:LOR) has approved a one-for-30 share consolidation in accordance with the authority granted by shareholders at the company’s annual meeting last November.  The stock closed Wednesday at 9 cents. The company has set May 25 as the record date for the share roll back, with trading on a consolidation adjusted [...]

Australia gives Lorus patent allowance for LOR-2040

Lorus Therapeutics (TSX:LOR) has received an allowance of a new patent in Australia for its LOR-2040 drug in the treatment of acute myeloid leukemia (AML). The Australian patent protects LOR-2040 as a single agent therapy and in combination therapies with cytarabine in AML.  This is Lorus’ first patent specific to treat AML with the combination [...]

Lorus posts positive Phase 2 leukemia results

Lorus Therapeutics (TSX:LOR) has obtained “favourable results” after successfully completed a Phase 2 trial with its LOR-2040 antisense drug candidate, in combination with cytarabine, in patients with acute myeloid leukemia (AML). The Steering Committee review determined that the phase 2 efficacy and safety results fulfilled the protocol criteria for continued patient enrolment and are consistent [...]